抑制肿瘤血管淋巴管生成的VEGFR分子机制及调控的研究进展

Research Progress on Molecular Mechanism and Regulation of VEGFR in Inhibiting Tumor Angiogenesis and Lymphangiogenesis

血管内皮生长因子受体(VEGFR)是靶向于血管与淋巴管生成的重要的信号分子,是人们研究抑制肿瘤药物的关键作用点,调控肿瘤新生淋巴管上的VEGFR可作为多种类型肿瘤的治疗靶点。由于作用于肿瘤新生淋巴管上的VEGFR的调控机制较为复杂,对抑制淋巴管生成的药物和肿瘤细胞转移之间复杂的相互作用关系了解甚少,为此,本文从血管内皮生长因子(VEGF)及VEGFR、肿瘤淋巴管生成及其调控因子、VEGF家族及其受体为靶点的淋巴管生成的调控、VEGFR为靶点的淋巴管抑制药物四个方面综述抑制肿瘤血管淋巴管生成的VEGFR分子机制及调控的研究进展,探讨肿瘤淋巴管生成中VEGF家族及其受体作用靶点的分子水平上的形成机制,探索可阻断相应作用靶点的理想型药物,为临床更好的治疗肿瘤提供思路。

Vascular endothelial growth factor receptor(VEGFR)is an important signaling molecule targeted to angiogenesis and lymphangiogenesis,and also a key action point for research on drugs that inhibit tumors.Regulating VEGFR on tumor lymphatic neogenesis can be used as therapeutic targets for many types of tumors.Due to the complex regulatory mechanism of VEGFR acting on tumor neonatal lymphatic vessels,little is known about the complex interaction relationship between drugs for inhibiting lymphangiogenesis and tumor cell metastasis.Therefore,In this paper,we review the research progress on the molecular mechanism and regulation of VEGFR that inhibits tumor angiogenesis from four aspects:vascular endothelial growth factor(VEGF)and VEGFR,tumor lymphangiogenesis and its regulatory factors,the regulation of VEGF family and its receptor-targeted lymphangiogenesis and VEGFR-targeted lymphatic inhibition drugs.We also explore the formation mechanism of VEGF family and its receptor targets at the molecular level in tumor lymphangiogenesis,and explore the ideal drugs that can block the corresponding action targets,so as to provide ideas for better clinical treatment of tumors.